This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Hormone Refractory Prostate Cancer
Information about Hormone Refractory Prostate Cancer: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Hormone Refractory Prostate Cancer
Most recent studies have shown that Hormone Refractory Prostate Cancer shares some biological mechanisms with adenocarcinoma, anemia, bone-neoplasms, bone-pain, carcinoma, malignant-neoplasm-of-prostate, malignant-neoplasms, metastatic-malignant-neoplasm-to-the-bone, metastatic-prostate-cancer, nausea, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, neoplasms-hormone-dependent, pain, prostate-adenocarcinoma, prostatic-neoplasms.
Among the many pathways, these few ones have gauged particular interests from scientists studying Hormone Refractory Prostate Cancer, and have been seen in publications frequently: Angiogenesis, Bone Resorption, Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Growth, Cell Killing, Cell Migration, Cell Proliferation, Coagulation, Drug Resistance, Immune Response, Induction Of Apoptosis, Localization, Pathogenesis, Programmed Cell Death, Secretion, Sensitization, Translation
Quite a number of genes have been found to play important roles in Hormone Refractory Prostate Cancer, such as ACTR1B, AKR1B1, AR, AREG, BCL2, BTG2, CBX8, CDKN1A, EGFR, ERBB2, FDXR, IL6, KLK3, NPEPPS, PCSK1, PLAG1, PROS1, PSAT1, VEGFA. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.